Status:
COMPLETED
Improved Effects of MI Plus Alpha-LA in PCOS
Lead Sponsor:
Lo.Li.Pharma s.r.l
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
20-35 years
Phase:
NA
Brief Summary
PCOS patients are initially treated with 2 g myo-inositol and 0.2 mg folic acid, two times per day by oral route, for three months. Among them, the subjects who have not ovulated despite this treatmen...
Detailed Description
Polycystic ovary syndrome is a complex chronic condition inducing several related disorders, such as subfertility and pregnancy complications. So far myo-inositol, successfully used in PCOS, has not b...
Eligibility Criteria
Inclusion
- patients affected by PCOS according to Rotterdam ESHRE-ASRM criteria, with anovulation and infertility \> 1 year
Exclusion
- presence of other conditions causing ovulatory dysfunction, such as hyperprolactinemia or hypothyroidism, or androgen excess, such as adrenal hyperplasia or Cushing's syndrome, and also in the case of intake of other drugs that can potentially influence the ovulation.
Key Trial Info
Start Date :
November 2 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2017
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT03422289
Start Date
November 2 2016
End Date
December 15 2017
Last Update
February 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Woman Health and Reproductive Medicine of Santo Spirito Hospital
Rome, Italy